Similar articles

• High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients.

  Rey D, Hoen B, Chavanet P, Schmitt MP, Hoizey G, Meyer P, Peytavin G, Spire B, Allavena C, Diemer M, May T, Schmit JL, Duong M, Calvez V, Lang JM. Rey D, et al. J Antimicrob Chemother. 2009 Feb;63(2):380-8. doi: 10.1093/jac/dkn471. Epub 2008 Nov 25. J Antimicrob Chemother. 2009. PMID: 19036752 Clinical Trial.
• Combination antiretroviral therapy with tenofovir, emtricitabine or lamivudine, and nevirapine.

  Redfield RR, Morrow JS. Redfield RR, et al. Clin Infect Dis. 2008 Oct 1;47(7):984-5. doi: 10.1086/591802. Clin Infect Dis. 2008. PMID: 18778234 No abstract available.
• Emerging mutations at virological failure of HAART combinations containing tenofovir and lamivudine or emtricitabine.

  Maserati R, De Silvestri A, Uglietti A, Colao G, Di Biagio A, Bruzzone B, Di Pietro M, Re MC, Tinelli C, Zazzi M; ARCA Collaborative Group. Maserati R, et al. AIDS. 2010 Apr 24;24(7):1013-8. doi: 10.1097/QAD.0b013e328336e962. AIDS. 2010. PMID: 20124969
• The continuing evolution of HIV therapy.

  Boyle BA. Boyle BA. AIDS Read. 2003 Dec;13(12):576-8, 582. AIDS Read. 2003. PMID: 14959692 Review. No abstract available.
• Tenofovir: what have over 1 million years of patient experience taught us?

  Pozniak A. Pozniak A. Int J Clin Pract. 2008 Aug;62(8):1285-93. doi: 10.1111/j.1742-1241.2008.01817.x. Int J Clin Pract. 2008. PMID: 18705824 Review.